Amorphical
Amorphous Calcium Carbonate Products
Startup F Health Tech & Life Sciences Est. 2004
Total Raised
$28.3M
F
Last Round
$6M
6 rounds
Investors
2
2 public
Team
3
11-50 employees
Confidence
93/100
News
7
articles
Patents
1
About
Amorphical is a pioneering biotechnology company that develops and manufactures unique natural-based medicines and dietary supplements with high bio-availability, aiming at the improvement of calcium absorption and management, in tandem with balancing the body's acidity level (pH) derived by various biomedical conditions. These features are critical for maintaining health, repairing bone deficiencies, treating severe diseases, and aiding the development and strengthening of the body. Amorphicalโ€™s leading scientists succeeded in stabilizing and preserving a rare natural form of calcium used by blue crayfish to develop a unique nanometric substance called amorphous calcium carbonate, which helps improve people's health and quality of life.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Materials & Substances
Target Customer
Industrial ManufacturingDiscrete IndustriesAerospaceHealthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcarePatients
Business Model
B2BB2B2C
Tags
pharmaceuticalssupplementsbiotechnologynutritioninvestorsprivate-investorspharma-companiesnovel-ingredientshospitalswellnessosteoporosiscancerspace-tech
Funding & Events
May 2016
E Round $8.8M
May 2013
Non-equity $2.7M
Mar 2014
C Round $8M
Mar 2010
A Round $1.8M
Undisclosed Investor(s)
Jan 2021
F Round $6M
Jan 2020
F Round $1M
ICU group
News (7)
Sep 30, 2025 ยท www.prnewswire.com
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...
Product StageFDA approved/pending approval
Sep 2, 2025 ยท www.prnewswire.com
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...
Management ChangesProduct Stage
Jun 13, 2022 ยท www.israelhayom.com
https://www.israelhayom.com/2022/06/13/israeli-shellfish-based-calcium-breakthrough-tested-in-space/
Jan 6, 2022 ยท newsdirect.com
growth-positive
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct
Customers
Dec 9, 2020 ยท www.calcalist.co.il
growth-positive
ืืžื•ืจืคื™ืงืœ ืฉืžืคื™ืงื” ืกื™ื“ืŸ ืžืกืจื˜ื ื™ื ื›ื—ื•ืœื™ื ื™ื•ืฆืืช ืœื’ื™ื•ืก ืฉืœ 30 ืžื™ืœื™ื•ืŸ ื“ื•ืœืจ ืœืคื™ ืฉื•ื•ื™ ืฉืœ 160 ืžื™ืœื™ื•ืŸ ื“ื•ืœืจ
Investment
Aug 3, 2017 ยท www.globes.co.il
growth-positive
Amorphical signs China calcium capsule deal
PartnersExpand
Mar 17, 2014 ยท www.globes.co.il
growth-positive
Amorphical calcium absorption trial successful
Investment
Details
Product Stage
Released
Employees
11-50
Exact Count
22
District
Center District
Founded
2004
Registrar
513562686
Crunchbase
amorphical
Locations
HaHarash Street 11, Nes Ziyyona, Israel
Links
Website
LinkedIn
Facebook
Admin
Last Update
Sep 2, 2025
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
markets, not claimed
Team (3)
Yossi Ben
Founder & Chairman
Founder
Eden Ben
CEO
Yigal Blum
CTO